RT Journal Article
SR Electronic
T1 1375 A hormone-based bispecific T cell engager (BiTE)-like molecule for the treatment of neuroendocrine tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A1429
OP A1429
DO 10.1136/jitc-2022-SITC2022.1375
VO 10
IS Suppl 2
A1 Eleonora Pelle
A1 Mauro Cives
A1 Elliot Medina
A1 Charlotte Mason
A1 Sebastian Snedal
A1 Xiomar Bustos Perez
A1 Leticia Tordesillas
A1 Miguel Gomez Fontela
A1 Renata Rossetti
A1 Gabriele Maiorano
A1 Vincent Luca
A1 Patrick Hwu
A1 Daniel Abate-Daga
A1 Jonathan Strosberg
YR 2022
UL http://jitc.bmj.com/content/10/Suppl_2/A1429.abstract
AB Background We designed a novel bispecific T-cell engager (BiTE) targeting the somatostatin receptor (SSTR), which is overexpressed by well-differentiated neuroendocrine tumors (NETs). In our BiTE, the single chain variable fragment (scFV) based anti-SSTR domain is replaced by 2 molecules of somatostatin-14 (SST14), the hormone that physiologically activates the SSTR.Methods The sequence of the SST14-scFV anti-CD3 BiTE was optimized and cloned into a pAcGP67avector. The recombinant protein was expressed by Trichoplusia-ni (High Five) using Baculovirus and isolated from the supernatant using nickel affinity chromatography. The binding potential of the BiTE towards CD3 and SSTR was determined by flow cytometry and confocal microscopy. The SSTR-specific T cell activation and the BiTE-induced cytotoxicity were measured after coincubation of CD3+ T cells isolated from the peripheral blood of healthy donors with 293T cells stably transduced to concurrently express SSTR and GFP, in presence of the BiTE. The same conditions in absence of BiTE or with the SSTR- parental 293T were used as negative control, while anti-CD3/CD28 beads were added as a positive control. The BiTE-induced cytotoxicity was assessed by real-time quantitative live-cell imaging using the Incucyte system. The BiTE-induced T cell activation was evaluated measuring the secretion of IFN-γ, and granzyme-B by ELISA.Results At a concentration of 100 nM, the BiTE bound the CD3 receptor of approximately 85% of T cells. By confocal microscopy, the BiTE was found to coat SSTR+293T cells. When added to SSTR+293T cell cultures, the BiTE by itself exerted antiproliferative activity (p <0.0001), possibly as result of an agonist activity on the SSTR. Such a cytotoxic effect was significantly more pronounced when T cells were also present in the cultures (p<0.0001). IFN-γ and granzyme-B secretion was significantly higher when the T cells were co-cultured with SSTR+293T cells in the presence of the BiTE as compared with parallel preparations with SSTR-293T cells or without the BiTE, suggesting that the BiTE-induced T cell activation is specific.Conclusions To our knowledge, this is the first BiTE to incorporate a hormone in one binding site. Our preclinical data indicate that the BiTE specifically engages the SSTR, the T cell receptor and induces a high level of cytotoxicity in the presence of T cells.